Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (23379)	7/20/1998 1:25:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

JO, Of course he would be much better off at a higher price. In most instances, the exercise price is close to $10, so there isn't much value at exercising at these depressed levels. Robinson has created the best pipeline in the business. The street keeps changing its method for Biotech valuations. Patient investors will be rewarded and the huge pipeline will pay handsome dividends, but for now the street clearly has a "show me" approach to most Biotechs, including LGND.